This inventor holds 58 USPTO granted patents and 2 published patent applications, plus 3 CIPO patents and 11 EPO patents, primarily in Cardiovascular Treatments (CPC class 2042). Top assignees: Sigma-Tau Industrie Farmaceutiche Riunite S.p.a., Diamond Shamrock Technologies S.a., Oronzio Denora Impianti Elettrochimici S.p.a.. Active years: 1976-2026.
Inventors with similar research interests:
Location History:
- Milan, I (1976)
- 20135 Milano, IT (1984)
- Milan MI, IT (1995)
- Rome, IT (2015 - 2020)
- Milan, IT (1976 - 2023)
Company Filing History:
14 out of 343 
10 out of 36 
6 out of 77 
Years Active: 1976-2026
Areas of Expertise:
Title: Giuseppe Bianchi: Innovative Contributions to Heart Failure Treatment
Introduction:
Giuseppe Bianchi, a Milan-based inventor, has made significant contributions to the field of medical science, specifically in the treatment of heart failure. With an impressive portfolio of 55 patents, Bianchi's innovative work has opened new possibilities for improving patients' health and well-being. This article delves into Bianchi's latest patents, highlights his career achievements, explores his notable collaborations, and recognizes his invaluable contributions to the field.
Latest Patents:
Bianchi's most recent patents showcase his expertise in developing novel compounds and formulations for the treatment of heart failure. Notably, one of his inventions, 17beta-heterocyclyl-digitalis like compounds, offers promising potential for acute or chronic heart failure treatment. These compounds, represented by formula (I), demonstrate the ability to enhance cardiac function and hold promise for oral administration.
In addition, Bianchi's istaroxime-containing intravenous formulation patent offers an innovative approach to treat acute heart failure (AHF). By extending the infusion of istaroxime or its metabolites for more than six hours, Bianchi's method avoids triggering arrhythmogenic events while effectively improving cardiac relaxation. This breakthrough has paved the way for safer and more efficient treatments for individuals suffering from AHF.
Career Highlights:
Giuseppe Bianchi's professional journey has included significant contributions to the pharmaceutical industry. He has worked with prestigious companies such as Sigma-tau Industrie Farmaceutiche Riunite S.p.a. and Diamond Shamrock Technologies S.a., where his innovative ideas and scientific expertise have flourished. Through his work, Bianchi has demonstrated a deep commitment to improving cardiovascular health and advancing the field of medicine.
Collaborations:
Throughout his career, Bianchi has had the privilege of collaborating with esteemed professionals in the field. Notably, he has worked alongside Patrizia Ferrari and Antonio Nidola, both of whom have contributed to the development of innovative treatments for heart failure. These collaborations have not only enhanced research efforts but have also fostered a culture of shared knowledge and expertise, resulting in remarkable advancements in the field.
Conclusion:
Giuseppe Bianchi's prolific career in the field of medical science, notably in heart failure treatment, has made a significant impact on patients' lives. With 55 patents to his name, including groundbreaking inventions for the treatment of heart failure, Bianchi has demonstrated exceptional skill and a deep understanding of the medical needs in this field. His collaborations with esteemed professionals further exemplify his commitment to advancing medical research. As we reflect on Bianchi's remarkable achievements, we eagerly anticipate his future contributions and the positive impact they will have on individuals suffering from heart failure.